Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19/BCMA CAR-T Cells Combined With Dasatinib in B-cell Malignancies
NCT04603872Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in B cell acute lymphoblastic leukemia (B-ALL), B-cell non-Hodgkin lymphoma (B-NHL) and multiple myeloma (MM) (2 arms), sponsored by Zhejiang University. Primary endpoints: Dose-limiting toxicity at 28 days and Treatment-emergent adverse events at 2 years. Started Nov 2020; status: recruiting.
02
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma (B-NHL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04603872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04603872.